vs

Side-by-side financial comparison of Ibotta, Inc. (IBTA) and Syndax Pharmaceuticals Inc (SNDX). Click either name above to swap in a different company.

Ibotta, Inc. is the larger business by last-quarter revenue ($82.5M vs $68.5M, roughly 1.2× Syndax Pharmaceuticals Inc). On growth, Syndax Pharmaceuticals Inc posted the faster year-over-year revenue change (791.7% vs -2.5%).

Ibotta, Inc. is an American mobile technology company headquartered in Denver, Colorado. Founded in 2011, the company offers cash back rewards on various purchases through its Ibotta Performance Network and direct to consumer app. Ibotta partners with CPG brands and network publishers to provide these rewards. As of 2024, the company operates solely in the United States. The company's rewards-as-a-service offering, the Ibotta Performance Network, went live in 2022.

Syndax Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oncology therapies for patients with hard-to-treat cancers. Its pipeline includes targeted and immunotherapy candidates addressing unmet medical needs, primarily serving global oncology healthcare stakeholders and patient populations.

IBTA vs SNDX — Head-to-Head

Bigger by revenue
IBTA
IBTA
1.2× larger
IBTA
$82.5M
$68.5M
SNDX
Growing faster (revenue YoY)
SNDX
SNDX
+794.2% gap
SNDX
791.7%
-2.5%
IBTA

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
IBTA
IBTA
SNDX
SNDX
Revenue
$82.5M
$68.5M
Net Profit
$-68.0M
Gross Margin
76.4%
Operating Margin
10.4%
-91.3%
Net Margin
-99.3%
Revenue YoY
-2.5%
791.7%
Net Profit YoY
27.8%
EPS (diluted)
$-0.43
$-0.78

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBTA
IBTA
SNDX
SNDX
Q1 26
$82.5M
Q4 25
$88.5M
$68.5M
Q3 25
$83.3M
$45.9M
Q2 25
$86.0M
$38.0M
Q1 25
$84.6M
$20.0M
Q4 24
$98.4M
Q3 24
$98.6M
$12.5M
Q2 24
$87.9M
Net Profit
IBTA
IBTA
SNDX
SNDX
Q1 26
Q4 25
$-68.0M
Q3 25
$1.5M
$-60.7M
Q2 25
$2.5M
$-71.8M
Q1 25
$555.0K
$-84.8M
Q4 24
Q3 24
$17.2M
$-84.1M
Q2 24
$-34.0M
Gross Margin
IBTA
IBTA
SNDX
SNDX
Q1 26
76.4%
Q4 25
78.7%
Q3 25
79.4%
Q2 25
79.2%
Q1 25
79.8%
Q4 24
84.6%
Q3 24
87.7%
Q2 24
86.0%
Operating Margin
IBTA
IBTA
SNDX
SNDX
Q1 26
10.4%
Q4 25
-1.9%
-91.3%
Q3 25
2.8%
-125.2%
Q2 25
1.4%
-182.7%
Q1 25
-3.3%
-417.9%
Q4 24
13.2%
Q3 24
21.0%
-716.6%
Q2 24
-24.6%
Net Margin
IBTA
IBTA
SNDX
SNDX
Q1 26
Q4 25
-99.3%
Q3 25
1.8%
-132.4%
Q2 25
2.9%
-189.3%
Q1 25
0.7%
-423.3%
Q4 24
Q3 24
17.5%
-673.0%
Q2 24
-38.6%
EPS (diluted)
IBTA
IBTA
SNDX
SNDX
Q1 26
$-0.43
Q4 25
$-0.03
$-0.78
Q3 25
$0.05
$-0.70
Q2 25
$0.08
$-0.83
Q1 25
$0.02
$-0.98
Q4 24
$3.04
Q3 24
$0.51
$-0.98
Q2 24
$-1.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBTA
IBTA
SNDX
SNDX
Cash + ST InvestmentsLiquidity on hand
$164.6M
$394.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$249.0M
$64.6M
Total Assets
$479.9M
$529.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBTA
IBTA
SNDX
SNDX
Q1 26
$164.6M
Q4 25
$186.6M
$394.1M
Q3 25
$223.3M
$436.0M
Q2 25
$250.5M
$455.2M
Q1 25
$297.1M
$512.2M
Q4 24
$349.3M
Q3 24
$341.3M
$389.6M
Q2 24
$317.9M
Total Debt
IBTA
IBTA
SNDX
SNDX
Q1 26
Q4 25
$0
Q3 25
Q2 25
Q1 25
Q4 24
$0
Q3 24
$0
Q2 24
$0
Stockholders' Equity
IBTA
IBTA
SNDX
SNDX
Q1 26
$249.0M
Q4 25
$287.7M
$64.6M
Q3 25
$329.6M
$115.4M
Q2 25
$354.1M
$157.4M
Q1 25
$401.3M
$215.1M
Q4 24
$457.3M
Q3 24
$378.0M
$366.4M
Q2 24
$359.7M
Total Assets
IBTA
IBTA
SNDX
SNDX
Q1 26
$479.9M
Q4 25
$525.9M
$529.7M
Q3 25
$569.4M
$551.8M
Q2 25
$600.8M
$596.1M
Q1 25
$639.3M
$640.7M
Q4 24
$678.4M
Q3 24
$598.3M
$425.8M
Q2 24
$556.0M
Debt / Equity
IBTA
IBTA
SNDX
SNDX
Q1 26
Q4 25
0.00×
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBTA
IBTA
SNDX
SNDX
Operating Cash FlowLast quarter
$30.4M
$-69.5M
Free Cash FlowOCF − Capex
$23.3M
FCF MarginFCF / Revenue
28.2%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$80.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBTA
IBTA
SNDX
SNDX
Q1 26
$30.4M
Q4 25
$27.8M
$-69.5M
Q3 25
$21.8M
$-70.5M
Q2 25
$25.9M
$-87.8M
Q1 25
$19.9M
$-95.2M
Q4 24
$22.0M
Q3 24
$39.5M
$-62.3M
Q2 24
$35.0M
Free Cash Flow
IBTA
IBTA
SNDX
SNDX
Q1 26
$23.3M
Q4 25
$20.3M
Q3 25
$14.5M
Q2 25
$22.2M
Q1 25
$18.0M
Q4 24
$21.8M
Q3 24
$39.2M
Q2 24
$34.8M
FCF Margin
IBTA
IBTA
SNDX
SNDX
Q1 26
28.2%
Q4 25
22.9%
Q3 25
17.4%
Q2 25
25.8%
Q1 25
21.2%
Q4 24
22.1%
Q3 24
39.8%
Q2 24
39.6%
Capex Intensity
IBTA
IBTA
SNDX
SNDX
Q1 26
Q4 25
8.5%
Q3 25
8.7%
Q2 25
4.2%
Q1 25
2.2%
Q4 24
0.2%
Q3 24
0.3%
Q2 24
0.2%
Cash Conversion
IBTA
IBTA
SNDX
SNDX
Q1 26
Q4 25
Q3 25
14.19×
Q2 25
10.38×
Q1 25
35.78×
Q4 24
Q3 24
2.29×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IBTA
IBTA

Redemption revenue$54.0M65%
Other$19.0M23%
Ad & other revenue$9.5M11%

SNDX
SNDX

Segment breakdown not available.

Related Comparisons